Our data also revealed that the H1047R mutation was considerably more common in SERMs/SERDs-received HR-positive /HER2-negative advanced BC patients or in radiotherapy-treated HER2 positive individuals, which strengthens the potential utility of cfDNA PIK3CA mutations as a tumour marker to guide treatment selection. This evidence concerns the gene ERBB2 and neoplasm.